Kiek dividendų moka WuXi AppTec Co 2025?
Pagal paskutinę informaciją nuo Liepa 2025, WuXi AppTec Co per paskutinius 12 mėnesių mokėjo bendrą dividendą, kuris sudarė 0,99 CNY už akciją. Esant dabartiniam WuXi AppTec Co kursui 77,15 CNY, tai atitinka 1,28 % dividendų grąžą.
Dividendai mokami kartus per metus.
1,28 % Dividendo grąža | = | 0,99 CNY Dividendas | 77,15 CNY akcijų kaina |
|
Ar WuXi AppTec Co dividendai yra saugūs?
WuXi AppTec Co kasmet didina dividendus jau 3 metus.
Per pastaruosius 10 metus WuXi AppTec Co kasmet 0 % sumažinta.
Per 5 metų laikotarpį augo išmokos padidėjo 27,311 %.
Analitikai prognozuoja, kad einamaisiais verslo metais Dividendų didinimas bus 7,458%.
WuXi AppTec Co Aktienanalyse
Ką daro WuXi AppTec Co?
WuXi AppTec Co Ltd is a Chinese company that was founded in 2000 and specializes in the development of customer-oriented services in the pharmaceutical research and in vitro diagnostics sectors. The company operates multiple facilities in China, the USA, Europe, and Singapore.
The business model of WuXi AppTec is based on the development and provision of services to meet the needs of customers worldwide. This includes activities such as bioanalysis, chemical development, drug manufacturing, and regulatory compliance and quality assurance services.
In terms of various industries, the company is divided into three main divisions.
The Chemical Division specializes in chemical development and drug manufacturing. The team has expertise in synthesizing complex molecules, scaling up for clinical trials, manufacturing bulk products for commercial use, and supplying APIs for formulation. The company has state-of-the-art facilities and technologies to ensure high product quality and fast production time.
The Medical Device Division provides in vitro diagnostics for the global market to enable rapid and reliable medical diagnosis. The focus is on developing innovative technologies and applications in the fields of oncology, infectious diseases, and neurology. The company has many partnerships with leading in vitro diagnostics companies to enhance the quality and reach of products and services.
The Biological Division specializes in the development of biopharmaceutical products and services. This includes the development of monoclonal antibodies to the production of recombinant proteins. The services include process development, manufacturing, characterization, and analysis of biological products. WuXi AppTec is at the forefront of technology and provides its customers with state-of-the-art facilities and technologies.
In addition to the aforementioned services, WuXi AppTec also offers solutions in the field of bioanalytics, supporting the development of analytical methods and drug validation.
The company has also recently expanded into other areas, including the acquisition of NextCODE Health, a firm specializing in genetic diagnostics and analysis tools.
The company operates internationally and collaborates with a wide range of customers in the pharmaceutical and biotech sectors. It is also part of a global network of companies focusing on therapeutic technologies, clinical trials, drug marketing, and other aspects of the pharmaceutical industry.
WuXi AppTec aims to provide its customers with high-quality products and services that are scientifically sound and effective. The company invests in research and development to provide its customers with the latest technologies and discoveries. WuXi AppTec Co yra viena populiariausių įmonių Eulerpool.com svetainėje.Akcijų taupymo planai siūlo patrauklią galimybę investuotojams ilgalaikėje perspektyvoje kurti turtą. Vienas pagrindinių privalumų yra vadinamasis vidutinės išlaidos efektas: reguliariai investuojant fiksuotą sumą į akcijas arba akcijų fondus, automatiškai perkama daugiau dalinių vertybių popierių, kai kainos yra žemos, ir mažiau – kai jos aukštos. Tai gali lemti palankesnę vidutinę dalies kainą per laiką. Be to, akcijų taupymo planai suteikia galimybę ir smulkiesiems investuotojams patekti į brangias akcijas, nes jie gali dalyvauti jau su mažomis sumomis. Reguliarus investavimas taip pat skatina disciplinuotą investavimo strategiją ir padeda išvengti emociškai pagrįstų sprendimų, pavyzdžiui, impulsyvaus pirkimo ar pardavimo. Be to, investuotojai gauna naudos iš potencialaus akcijų vertės augimo bei iš dividendų, kurie gali būti reinvestuoti, kas sustiprina sudėtinio palūkanų efektą ir taip skatina investuoto kapitalo augimą.